# Lttl reviews (2026): GLP-1 telehealth sellers | This GLP Every line publishes a four-rung prepay ladder, and the low-dose and standard-dose products are priced separately rather than blended. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/lttl Updated: 2026-10-28 Partner By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Four rungs, two dose lines # Lttl review Every line publishes a four-rung prepay ladder, and the low-dose and standard-dose products are priced separately rather than blended. ## The verdict Lttl prices its low-dose semaglutide injection at $149 month to month and publishes the whole prepay ladder beneath it: $129 quarterly, $119 every six months and $109 annually. A separate standard-dose line, up to 2.4mg, runs $99 per four-week fill on auto-refill, where a fifty-two-week block bills $1,068. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Dose pricing Flat across doses Injection From $107/mo Oral From $194/mo Prescription Required Compounded Yes — not FDA-approved Lttl splits its catalog by dose rather than only by molecule, which is unusual and useful. A low-dose line marketed for tolerability sits beside a standard-dose line going up to 2.4mg, and each carries its own price and its own ladder. Both molecules appear, with tirzepatide described as a low-dose GLP-1 and GIP product on the same ladder as the microdose semaglutide. 1. ## Who writes the prescription, and what do they see? A prescription precedes dispensing and the service runs remotely. What the pages give a reader instead of clinician detail is dose framing, which is the rarer of the two. Knowing that a line is a low-dose product marketed for tolerability tells a buyer something about what they will be taking. A clinician's name usually does not. The prepay ladder is the mechanism the whole service is built around, and Lttl publishes all four rungs rather than advertising the deepest one and leaving the rest to checkout. There is also a first-month special at $119 on the low-dose lines and $149 on the oral, which is a separate device again — it lowers one bill without touching any of the four ongoing rates. 2. ## What happens when the dose goes up? Lttl states the rate holds at every dose, and the two-line structure is what makes that claim legible. The low-dose product is priced as a low-dose product. A buyer moving to standard dosing moves to the separate $99 line rather than climbing a hidden ladder on the first. The standard line's own note caps it at 2.4mg, so the range each figure covers is stated. 3. ## What the price includes The month-to-month figure is $149 and the annual rung is $109, so committing a year takes $40 a month off the same product — and the pages show every step between. The oral runs the same shape at $179 month to month down to $139 annually. The standard-dose line is the one to read carefully: $99 per four-week fill is thirteen fills a year, which is why the fifty-two-week block bills $1,068 rather than $1,188. 4. ## What it claims, and what it cites Every line is a compounded preparation, which places all of them outside the FDA review that an approved product completes before dispensing. The low-dose products are marketed for tolerability rather than for a different clinical effect, and the pages do not claim otherwise. ## Where it holds up, and where it does not - Strength: All four prepay rungs published - Strength: Low-dose and standard-dose priced separately - Strength: Rate stated to hold at every dose - Strength: The four-week fill cycle is disclosed - Limitation: The lowest rung needs a year committed - Limitation: Standard line bills thirteen times a year - Limitation: First-month special applies once - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about Lttl. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants to see every prepay rung before choosing a term, and who knows which dose line they need. Wrong for A reader who wants a single monthly figure with no term to choose. ## The evidence behind what Lttl prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Lttl compares | Seller | Who it suits | Go | | --- | --- | --- | | June Health | A reader who wants the cost of escalating known at enrollment, not at month three | | | Lean Meds | Readers willing to clarify the prescription and renewal details | | | Trimi Health | A reader who can pay a year at once, or finance it, and wants the per-month figure to stop moving as the dose rises. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Enhanced](https://thisglp.com/reviews/enhanced) [EverFit Medical](https://thisglp.com/reviews/everfit-medical) [Evergreen Telehealth](https://thisglp.com/reviews/evergreen-telehealth) [Evernow](https://thisglp.com/reviews/evernow) [Evolve Telemed](https://thisglp.com/reviews/evolve-telemed) [FeelGood](https://thisglp.com/reviews/feelgood-meds) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What is the difference between the $149 and $99 lines? Dose. The $149 is a low-dose product marketed for tolerability; the $99 is the standard-dose line running up to 2.4mg, billed per four-week fill on auto-refill. What does the annual plan save? $40 a month against the month-to-month rate on the low-dose injection, taking $149 down to $109, with $129 quarterly and $119 half-yearly in between. Why does a year cost $1,068 rather than twelve times $99? Because the standard line bills per four-week fill, which is thirteen fills across fifty-two weeks. Lttl publishes the block figure rather than leaving the arithmetic to the buyer. Is Lttl expensive compared with other GLP-1 telehealth sellers? Lttl publishes a starting figure of $107/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Lttl below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms).